Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;6(2):361-8.
doi: 10.2215/CJN.04560510. Epub 2010 Oct 7.

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease

Affiliations

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease

Esther Meijer et al. Clin J Am Soc Nephrol. 2011 Feb.

Abstract

Background and objectives: Experimental studies suggest a detrimental role for vasopressin in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, it is unknown whether endogenous vasopressin concentration is associated with disease severity in patients with ADPKD.

Design, setting, participants, & measurements: Plasma copeptin concentration (a marker of endogenous vasopressin levels) was measured in 102 ADPKD patients (diagnosis based on Ravine criteria) by an immunoassay. Plasma and urinary osmolarity were also measured. To assess disease severity, GFR and effective renal blood flow were measured by continuous infusion of 125I-iothalamate and 131I-hippuran, total renal volume by magnetic resonance imaging, and 24-hour urinary albumin excretion by nephelometry.

Results: In these ADPKD patients, copeptin was associated with the various markers of disease severity in ADPKD (positively with total renal volume [R=0.47] and albuminuria [R=0.39] and negatively with GFR [R=-0.58] and effective renal blood flow [R=-0.52], all P<0.001). These associations were independent of age, gender, and use of diuretics. Copeptin was furthermore associated with plasma osmolarity (P<0.001) but not with 24-hour urinary volume, 24-hour urinary osmolarity or fractional urea excretion (P=0.7, 0.9, and 0.3, respectively).

Conclusions: On cross-sectional analysis, copeptin is associated with disease severity in ADPKD patients, supporting the results of experimental studies that suggest that vasopressin antagonists have a renoprotective effect in ADPKD and offering a good prospect for clinical studies with these agents.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Association between plasma osmolarity and copeptin (overall R = 0.53, P < 0.001; males ▴ and —, R = 0.40, P = 0.003; and females ○ and – –, R = 0.46, P = 0.002).
Figure 2.
Figure 2.
VP in association with markers of disease severity in ADPKD (males ▴ and —; females ○ and – –). On the left, associations between copeptin and TRV (upper left; overall: R = 0.47, P < 0.001; males: R = 0.37, P = 0.006; females: R = 0.37, P = 0.01) and 24-hour UAE (lower left; overall: R = 0.39, P < 0.001; males: R = 0.30, P = 0.03; females: R = 0.29, P = 0.07). On the right, associations between log copeptin and ERBF (upper right; overall R = −0.52, P < 0.001; males: R = −0.57, P < 0.001; females: R = −0.61, P < 0.001) and GFR (lower right; overall R = −0.58, P < 0.001, males: R = −0.58, P < 0.001; females: R = −0.61, P < 0.001).

Similar articles

Cited by

References

    1. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 81: 289–298, 1995 - PubMed
    1. Peters DJ, Spruit L, Saris JJ, Ravine D, Sandkuijl LA, Fossdal R, Boersma J, van ER, Norby S, Constantinou-Deltas CD: Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 5: 359–362, 1993 - PubMed
    1. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332–342, 1993 - PubMed
    1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287–1301, 2007 - PubMed
    1. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372–390, 2001 - PubMed

MeSH terms